Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)

Summary

The specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average Epogen utilization. Statin naive patients on maintenance HD will be started on 20mg atorvastatin daily for weeks and then titrated up to 40mg atorvastatin daily for an additional 12 weeks. Patient's inflammatory markers (ferritin, CRP) and weekly Epogen usage will be monitored.

Timeline

Start

2016-03-04

Primary completion

2017-03-22

Completion

2017-03-22

Drugs

Indications